Board of Governors of the Federal Reserve System, November 14, 1996.

William W. Wiles,

Secretary of the Board.

[FR Doc. 96–29600 Filed 11-19-96; 8:45 am]

BILLING CODE 6210-01-F

Notice of Proposals To Engage in Permissible Nonbanking Activities or To Acquire Companies That are Engaged in Permissible Nonbanking Activities

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.25 of Regulation Y (12 CFR 225.25) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act, including whether consummation of the proposal can ''reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices'' (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 4, 1996.

A. Federal Reserve Bank of Cleveland (R. Chris Moore, Senior Vice President) 1455 East Sixth Street, Cleveland, Ohio 44101:

1. Mid Am, Inc., Bowling Green, Ohio; to engage *de novo* through its subsidiary, Mid Am Private Trust, National Association, Cincinnati, Ohio, in performing functions or activities of a trust company, pursuant to § 225.25(b)(3) of the Board's Regulation Y.

B. Federal Reserve Bank of Richmond (Lloyd W. Bostian, Jr., Senior Vice President) 701 East Byrd Street, Richmond, Virginia 23261:

1. Southern National Corporation, Winston-Salem, North Carolina, and BB&T Financial Corporation of Virginia, Virginia Beach, Virginia; to acquire Fidelity Financial Bankshares Corporation, Richmond, Virginia, and thereby indirectly acquire Fidelity Federal Savings Bank, Richmond, Virginia, and thereby engage in operating a savings institution, pursuant to § 225.25(b)(9) of the Board's Regulation Y, and in holding limited partnership interests in funds that invest in partnerships which own and operate low income rental properties, pursuant to § 225.25(b)(6) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, November 14, 1996.

William W. Wiles,

Secretary of the Board.

[FR Doc. 96–29601 Filed 11-19-96; 8:45 am]

BILLING CODE 6210-01-F

Sunshine Act Meeting Notice

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 11:00 a.m., Monday, November 25, 1996.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 21st Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Federal Reserve Bank and Branch director appointments.
2. Proposed procedural amendments to the Federal Reserve System Retirement Plan.
3. Proposed acquisition of automated data processing equipment within the Federal Reserve System.
4. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.
5. Any items carried forward from a previously announced meeting.

Contact Person for More Information: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204. You may call (202) 452–3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: November 15, 1996.

William W. Wiles,

Secretary of the Board.

[FR Doc. 96–29764 Filed 11–18–96; 10:35 am]

BILLING CODE 6210–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96N–0279]

Agri-Tech, Inc.; Proposal To Withdraw Approval of a New Animal Drug Application; Opportunity for a Hearing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is providing an opportunity for a hearing on a proposal to withdraw approval of a new animal drug application (NADA) for Protamone-D (iodinated casein tablets), held by Agri-Tech, Inc., because the applicant has failed to submit required periodic reports.

DATES: Requests for a hearing with data, analysis, and information relied upon to justify a request for a hearing are due by December 20, 1996.

ADDRESSES: Requests for a hearing, supporting data, and other comments filed in response to this notice should be identified with Docket No. 96N–0279 and sent to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Mohammad I. Sharar, Center for Veterinary Medicine (HFV–216), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0159.

SUPPLEMENTARY INFORMATION: An applicant is required to report periodically to the Center for Veterinary Medicine (CVM) concerning each of the applicant's approved NADA's as provided in § 510.300 (21 CFR 510.300). Agri-Tech, Inc., 4722 Broadway, Kansas City, MO 64112 (last known address), is the sponsor of NADA 13–502 which provides for oral use of Protamone-D (iodinated casein tablets) in dogs. Agri-Tech, Inc., has not submitted the required periodic reports for NADA 13–502 and has not responded to CVM's requests for submission of those reports. Letters to the firm have been returned indicating the firm is no longer at the above-listed address.

Therefore, notice is given to Agri-Tech, Inc., and to all other interested persons who may be adversely affected, that the Director, CVM, proposes to issue an order under section 512(e) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360b(e)) withdrawing approval of NADA 13–502 and all amendments and supplements thereto on the ground that the applicant has failed to submit the reports required under § 510.300. Upon withdrawal of NADA 13–502, the corresponding regulation (21 CFR 520.1157) will be revoked.

In accordance with the provisions of section 512 of the act and regulations issued under it (parts 510 and 514 (21 CFR parts 510 and 514)), and under authority delegated to the Director, CVM (§ 5.84 (21 CFR 5.84)), CVM hereby provides the applicant an opportunity for a hearing to show why approval of the NADA and all amendments and supplements thereto should not be withdrawn (and the corresponding regulations revoked) and an opportunity to raise, for administrative determination, all issues relating to the legal status of the application and drug products approved thereunder. Any hearing would be subject to the provisions of 21 CFR part 12.

An applicant who decides to seek a hearing shall file on or before December 20, 1996, a written notice of appearance, request for a hearing, and the data, information, and analyses relied on to justify a hearing as specified in § 514.200.

Procedures and requirements governing this notice of opportunity for a hearing, notice of appearance and request for hearing, submission of information and analysis to justify a hearing, other comments, and a grant or denial of a hearing, are contained in § 514.200.

The failure of an applicant to file a timely, written notice of appearance and request for a hearing as required by § 514.200 constitutes an election by the applicant not to make use of the opportunity for a hearing concerning the proposed action and constitutes a waiver of any contentions about the legal status of the product. In such case, the Director, CVM, under the authority delegated to him in § 5.84(a)(2), will, without further notice, enter a final order withdrawing approval of the application. Thereafter, the product may not be legally marketed, and CVM may begin appropriate regulatory action to remove it from the market. Any new animal drug product which is not the subject of an approved application is subject to regulatory action at any time.

A request for a hearing may not rest upon mere allegations or denials, but must set forth specific facts showing that there is a genuine and substantial issue of fact that justifies a hearing. Reports submitted to remedy the deficiencies must be complete in all respects as required by § 510.300. If it is clear that the reports submitted are not complete or that there is no genuine and substantial issue of fact that precludes the withdrawal of approval, or that the request for a hearing is not made in the required format or with the required analysis, the Commissioner of Food and Drugs will enter summary judgment against the person who requests the hearing, making findings and conclusions, and denying a hearing. If a hearing is requested and is justified by the sponsor's response to this notice, the issues will be defined, an administrative law judge will be assigned, and a written notice of the time and place at which the hearing will begin will be issued.

All submissions pursuant to this notice shall be filed in two copies. Except for information prohibited from public disclosure under 21 U.S.C. 331(j) or 18 U.S.C. 1905, the submissions may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 512(e) (21 U.S.C. 360b(e))) and under authority delegated to the Director, CVM (§ 5.84).

Dated: October 18, 1996.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 96–29630 Filed 11–19–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96F–0382]

Milwhite, Inc.; Filing of Food Additive Petition (Animal Use) Hydrated Sodium Calcium Aluminosilicate

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Milwhite, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of hydrated sodium calcium aluminosilicate as a binder for aflatoxins in feeds.

DATES: Written comments on the petitioner's environmental assessment by January 21, 1997.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Henry E. Ekperigin, Center for Veterinary Medicine (HFV–222), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1724.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 2230) has been filed by Milwhite, Inc., 7050 Portwest Dr., suite 190, Houston, TX 77024. The petition proposes to amend the food additive regulations in part 573 *Food Additives Permitted in Feed and Drinking Water of Animals* (21 CFR part 573) to provide for the safe use of hydrated sodium calcium aluminosilicate as a binder for aflatoxins in feeds.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before January 21, 1997 submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's findings of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: November 1, 1996.

Michael J. Blackwell,

Deputy Director, Center for Veterinary Medicine.

[FR Doc. 96–29632 Filed 11–19–96; 8:45 am]

BILLING CODE 4160–01–F